Skip to content
Clinical Trials – home

Turku University Hospital

Verified siteinfo

Finland Kiinamyllynkatu 4-8, 20520 Turku, Finland

  • 85 trials recruiting
  • Non-small cell lung cancer · Prostate cancer · Chronic kidney disease
  • Adults and children

About Specializations

Turku University Hospital in Turku, Finland specialises in clinical trials of conditions such as Non-small cell lung cancer, Prostate cancer, Chronic kidney disease, Endometrial cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases at Turku University Hospital

Clinical research at this Heart Center focuses on cardiovascular diseases, with a strong emphasis on coronary artery disease. The studies are designed to evaluate better treatment options for people undergoing percutaneous coronary intervention, especially those who may face a higher bleeding risk.

  • Comparing drug-coated balloons with drug-eluting stents for coronary artery disease
  • Studying treatment approaches for patients with acute coronary syndromes
  • Assessing care strategies for patients at increased bleeding risk

These trials aim to improve the safety and effectiveness of heart disease treatment while supporting more personalized decisions about antiplatelet therapy and device-based care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Kiinamyllynkatu 4-820520 TurkuFinland
Recruiting now
85 trials
Conditions studied
142
Partner status
Verified site

More sites in TurkuFinland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

208 clinical trials

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:FinlandFinland
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.